3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6,7,8-tetrahydroquinoline, 95%, 100mg

1-(9H-Fluoren-9-yl)-3-oxo-2,7,10,13,16,19,22,25,28-nonaoxa-4-azahentriacontan-31-oic acid, 97%, 10g

3,6,9,12-TETRAOXAPENTADEC-14-YN-1-AMINE, 95.0%, 5g

6-Bromo-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-2-one, 95.0%, 5g

Ether monoéthylique de propylèneglycol, min 99%, pour la synthèse, 1L, emballage plastique.

(5-(Trifluoromethyl)-1H-pyrazol-4-yl)boronic acid, 95.0%, 1g

Dicyclohexyl(3-isopropoxy-2',4',6'-triisopropyl-[1,1'-biphenyl]-2-yl)phosphine, 98%, 5g

5-(1H-Benzoimidazol-2-yl)-pentanoic acid, 250mg

1-(2-Bromo-1,1-difluoroethyl)-4-fluorobenzene, 97.0%, 250mg

6-Bromobenzofuran-2-carboxylic acid, 95.0%, 5g

(4-{[6-(Trifluoromethyl)pyridin-2-yl]oxy}phenyl)methanol, 97.0%, 5g

2-(3-Bromophenyl)-1,3,4-oxadiazole, 95+%, 250mg

Ceftriaxone Sodium Salt, 98.0%, 5g